Evaluating the validity of animal models for research into therapies for immune-based disorders

Drug Discovery Today

Volumn 9, Issue 12, 2004, Pages 517-524

  'T Hart, Bert A ^a   Amor, Sandra ^a   Jonker, Margreet ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

animal models; chronic diseases; Drug Discovery; Molecular Medicine; non human primates; Physiology; preclinical testing; rodents; transplantation

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BASILIXIMAB; BETA INTERFERON; CANNABIS; CD40 LIGAND MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR; CLADRIBINE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; ESTRIOL; ETANERCEPT; EVEROLIMUS; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; OKT 4; RAPAMYCIN; ROQUINIMEX; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

AUTOIMMUNE DISEASE; BIOTECHNOLOGICAL PROCEDURES; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HUMAN; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL RESEARCH; MOLECULE; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOCIETY; VACCINATION; VALIDATION PROCESS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; ORGAN TRANSPLANTATION;

EID: 2942585381     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03112-5     Document Type: Review

References (65)

1. Herrmann D.B., Bicker U. Drugs in autoimmune diseases. Klin. Wochenschr. 68:(Suppl 21):1990;15-25
2. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497
3. Yelton D.E., Scharff M.D. Monoclonal antibodies: a powerful new tool in biology medicine. Annu. Rev. Biochem. 50:1981;657-680
4. Conner C.S. Therapy with monoclonal antibodies. Drug Intell. Clin. Pharm. 18:1984;65-66
5. Cosimi A.B., et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N. Engl. J. Med. 305:1981;308-314
6. Ritz J., Schlossman S.F. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood. 59:1982;1-11
7. Seaman W.E., et al. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J. Immunol. 130:1983;1713-1718
8. Sriram S., Steinman L. Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J. Exp. Med. 158:1983;1362-1367
9. McDevitt H.O., et al. Monoclonal anti-Ia antibody therapy in animal models of autoimmune disease. Ciba Found. Symp. 129:1987;184-193
10. Feldmann M., et al. Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. Prog. Growth Factor Res. 4:1992;247-255
11. Contag P.R. Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov. Today. 7:2002;555-562
12. Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology. 61:(Suppl 5):2003;S13-S17
13. Rosenberg A.S. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel). 112:2003;15-21
14. Osbourn J., et al. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discov. Today. 8:2003;845-851
15. Adams A.B., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 111:2003;1887-1895
16. Sachs D.H. Tolerance: Of mice and men. J. Clin. Invest. 111:2003;1819-1821
17. Mestas J., Hughes C.C. Of Mice and Not Men: Differences between Mouse and Human Immunology. J. Immunol. 172:2004;2731-2738
18. Buhler L.H., et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 74:2002;1405-1409
19. Fuchimoto Y., et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J. Clin. Invest. 105:2000;1779-1789
20. Starzl T.E., et al. The clinical use of antilymphocyte globulin in renal homotransplantation. Transplantation. 5:1967;1100-1105. (Suppl)
21. Cosimi A.B. OKT3: First-dose safety and success. Nephron. 46:(Suppl 1):1987;12-18
22. Kirk A.D., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 76:2003;120-129
23. Thomas J.M., et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation. 68:1999;1660-1673
24. Kraan M.C., et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum. 41:1998;1481-1488
25. 't Hart B.A., et al. Non-invasive measurement of brain damage in a primate model of multiple sclerosis. Trends Mol. Med. 10:2004;85-91
26. 't Hart B.A., et al. Gene therapy in nonhuman primate models of human autoimmune disease. Gene Ther. 10:2003;890-901
27. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet. 358:2001;903-911
28. Sany J. Immunological treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 8:(Suppl 5):1990;81-88
29. Breedveld F.C. Monoclonal antibodies to CD4. Rheum. Dis. Clin. North Am. 24:1998;567-578
30. Tak P.P., et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum. 38:1995;1457-1465
31. Choy E.H., et al. Monoclonal antibody therapy in rheumatoid arthritis. Br. J. Rheumatol. 37:1998;484-490
32. Choy E.H., et al. Innovative treatment approaches for rheumatoid arthritis. T-cell regulation. Baillieres Clin. Rheumatol. 9:1995;653-671
33. VanderBorght A., et al. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin. Arthritis Rheum. 31:2001;160-175
34. Keffer J., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10:1991;4025-4031
35. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344:2001;907-916
36. Probert L., et al. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur. J. Immunol. 25:1995;1794-1797
37. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 16:2002;183-200
38. Coles A.J., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 354:1999;1691-1695
39. Miller D.H., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:2003;15-23
40. Brok H.P., et al. Non-human primate models of multiple sclerosis. Immunol. Rev. 183:2001;173-185
41. Boon L., et al. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J. Immunol. 167:2001;2942-2949
42. Laman J.D., et al. Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur. J. Immunol. 32:2002;2218-2228
43. Brok H.P., et al. Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody. J. Immunol. 169:2002;6554-6563
44. 't Hart, B.A., et al. Therapeutic effects of anti-IL-12p40 antibody on pre-existing brain white matter lesions in the common marmoset model of autoimmune encephalomyelitis. (in press)
45. Balner H. Testing anti-human lymphocyte sera in subhuman primates. Lancet. 1:1970;848
46. Todo S., et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery. 104:1988;239-249
47. Schuurman H.J., et al. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation. 69:2000;737-742
48. Shapiro M.E., et al. Monoclonal anti-IL-2 receptor antibody in primate renal transplantation. Transplant. Proc. 19:1987;594-598
49. Waldmann H., Cobbold S. The use of monoclonal antibodies to achieve immunological tolerance. Immunol. Today. 14:1993;247-251
50. Vincenti F. New monoclonal antibodies in renal transplantation. Minerva Urol. Nefrol. 55:2003;57-66
51. Cobbold S.P., et al. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol. Rev. 129:1992;165-201
52. Lehmann M., et al. Anti-CD4 monoclonal antibody-induced allograft tolerance in rats despite persistence of donor-reactive T cells. Transplantation. 64:1997;1181-1187
53. Jonker M., et al. OKT4 and OKT4A antibody treatment as immunosuppression for kidney transplantation in rhesus monkeys. Transplantation. 39:1985;247-253
54. Cosimi A.B., et al. Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. Surgery. 108:1990;406-413
55. Mourad G.J., et al. Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys. Transplantation. 65:1998;632-641
56. Larsen C.P., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381:1996;434-438
57. Montgomery S.P., et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 74:2002;1365-1369
58. Birsan T., et al. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation. 75:2003;2106-2113
59. Pearson T.C., et al. Transplantation tolerance induced by CTLA4-Ig. Transplantation. 57:1994;1701-1706
60. Pearson T.C., et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation. 74:2002;933-940
61. Haanstra K.G., et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation. 75:2003;637-643
62. Smith R.M., et al. Prolongation of murine vascularized heart allograft survival by recipient-specific anti-major histocompatibility complex class II antibody. Transplantation. 64:1997;525-528
63. Luke P.P., et al. Anti-CD45RB monoclonal antibody-mediated transplantation tolerance. Curr. Mol. Med. 1:2001;533-543
64. Goodman S., Check E. The great primate debate. Nature. 417:2002;684-687
65. Jonker M., et al. Treatment with anti-MHC class II antibody postpones kidney allograft rejection in primates but increases the risk of CMV activation. Am. J. Transpl. 2004;. (in press)